Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data

SIMPLE SUMMARY: The management of non-small cell lung cancer with a common EGFR mutation has evolved over the past decades. While frontline use of second- or third-generation EGFR tyrosine kinase inhibitors (TKIs) is preferred over first-generation EGFR-TKIs, choosing the ideal agent depends on mult...

Descripción completa

Detalles Bibliográficos
Autores principales: Marin-Acevedo, Julian A., Pellini, Bruna, Kimbrough, ErinMarie O., Hicks, J. Kevin, Chiappori, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913773/
https://www.ncbi.nlm.nih.gov/pubmed/36765587
http://dx.doi.org/10.3390/cancers15030629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913773/
https://www.ncbi.nlm.nih.gov/pubmed/36765587
http://dx.doi.org/10.3390/cancers15030629

Ejemplares similares